Tower Research Capital (TRC)’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.6K | Buy |
16,799
+3,213
| +24% | +$2.6K | ﹤0.01% | 3858 |
|
|
2025
Q1 | $10.4K | Buy |
13,586
+3,210
| +31% | +$2.47K | ﹤0.01% | 3637 |
|
|
2024
Q4 | $13.2K | Buy |
10,376
+5,074
| +96% | +$6.47K | ﹤0.01% | 3548 |
|
|
2024
Q3 | $11K | Sell |
5,302
-1,762
| -25% | -$3.65K | ﹤0.01% | 3705 |
|
|
2024
Q2 | $26.9K | Buy |
7,064
+3,717
| +111% | +$14.2K | ﹤0.01% | 3567 |
|
|
2024
Q1 | $15.9K | Sell |
3,347
-645
| -16% | -$3.06K | ﹤0.01% | 3218 |
|
|
2023
Q4 | $17K | Buy |
3,992
+492
| +14% | +$2.1K | ﹤0.01% | 3751 |
|
|
2023
Q3 | $10.8K | Buy |
3,500
+1,410
| +67% | +$4.36K | ﹤0.01% | 4075 |
|
|
2023
Q2 | $9.41K | Sell |
2,090
-11,262
| -84% | -$50.7K | ﹤0.01% | 4266 |
|
|
2023
Q1 | $76K | Buy |
13,352
+9,820
| +278% | +$55.9K | ﹤0.01% | 2120 |
|
|
2022
Q4 | $21K | Buy |
3,532
+2,278
| +182% | +$13.5K | ﹤0.01% | 3099 |
|
|
2022
Q3 | $9K | Sell |
1,254
-2,770
| -69% | -$19.9K | ﹤0.01% | 4678 |
|
|
2022
Q2 | $21K | Buy |
4,024
+1,689
| +72% | +$8.81K | ﹤0.01% | 3752 |
|
|
2022
Q1 | $16K | Sell |
2,335
-2,985
| -56% | -$20.5K | ﹤0.01% | 3766 |
|
|
2021
Q4 | $66K | Buy |
5,320
+1,821
| +52% | +$22.6K | ﹤0.01% | 2543 |
|
|
2021
Q3 | $109K | Buy |
3,499
+2,434
| +229% | +$75.8K | ﹤0.01% | 2332 |
|
|
2021
Q2 | $31K | Sell |
1,065
-1,740
| -62% | -$50.6K | ﹤0.01% | 3458 |
|
|
2021
Q1 | $122K | Buy |
2,805
+2,600
| +1,268% | +$113K | ﹤0.01% | 2436 |
|
|
2020
Q4 | $15K | Buy |
+205
| New | +$15K | ﹤0.01% | 4053 |
|